

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

St. Joseph's Hospital, Phoenix, Arizona, United States
Pediatric Clinical Research Center, Children's Hospital Oakland, Oakland, California, United States
The Children's Hospital, Denver, Colorado, United States
Harbin Clinic, Rome, Georgia, United States
Mid-Illinois Hematology and Oncology Associates, Normal, Illinois, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Children's Hospital Boston, Boston, Massachusetts, United States
Saint Louis University Cardinal Glennon Children's Hospital, St. Louis, Missouri, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Upstate Medical University, State University of New York (SUNY), Syracuse, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Baylor College of Medicine Texas Children's Hospital, Houston, Texas, United States
University of Utah Hospital, Salt Lake City, Utah, United States
Franciscan Skemp Healthcare, La Crosse, Wisconsin, United States
Fundacao Universidade de Ciencias da Saude de Alagoas Governador Lamenha Filho / UNCISAL, Maceio, AL, Brazil
Clinica Casa de Saude Sao Joao, Barreiras, BA, Brazil
c-HUPES/UFBA, Salvador, BA, Brazil
Hospital Universitario da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul, Campo Grande, MS,
Instituto de Puericultura e Pediatria Martagao Gesteira / Hospital Pediatrico, Rio de Janeiro, RJ, Brazil
Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica, Porto Alegre, RS, Brazil
UNIFESP Instituto de Oncologia Pediatrica, Sao Paulo, SP, Brazil
Instituto da Crianca / Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP,
The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada
University of Montreal / Hopital Ste-Justine, Montreal, Quebec, Canada
Hopital Edouard Herriot, Lyon, , France
Hopital de Hautepierre, Strasbourg Cedex, , France
Hopital Ducuing, Toulouse Cedex, , France
Universitätsklinikum Aachen Kinderklinik, Aachen, , Germany
Universitätsklinik Dusseldorf Kinderklinik, Dusseldorf, , Germany
Justus-Liebig Universität, Giessen, , Germany
Universitätsklinikum Göttingen, Göttingen, , Germany
Universitätsklinikum Hamburg Eppendorf, Hamburg, , Germany
Children's University Hospital Mainz AG, Mainz, , Germany
Università Milano Bicocca / Ospedale S. Gerardo, Monza (Milano), , Italy
Università degli Studi di Napoli Federico II, Napoli, , Italy
Università di Padova, Padova, , Italy
Ospedale S. S. Annunziata, Savigliano (Cuneo), , Italy
Spitalul Clinic de Copii, Cluj Napoca, Cluj, Romania
University Hospital Germans Trias i Pujol, Badalona, , Spain
Servicio de Pediatria, Linares (Jaen), , Spain
Drottning Silvias Barnsjukhus, Gothenberg, , Sweden
Karolinska University Hospital, Stockholm, , Sweden
Bath and NE Somerset Primary Care Trust, Bath, , United Kingdom
Addenbrooke's Hospital, Cambridge, , United Kingdom
Derbyshire Children's Hospital, Derby, , United Kingdom
Royal Hospital for Sick Children, Glasgow, , United Kingdom
Great Ormond Street Hospital for Sick Children, London, , United Kingdom
Royal Manchester Children's Hospital, Manchester, , United Kingdom
Royal Victoria Infirmary, Newcastle, , United Kingdom
Royal Surrey County Hospital, Surrey, , United Kingdom

Study TKT024EXT was a long-term, single-arm, open-label extension of Study TKT024, a one year Phase 2/Phase 3 registration study. The primary objective of this extension study was to collect long-term safety and clinical outcome data in Mucopolysaccharidosis II (MPS II), also known as Hunter Syndrome, from the Phase 2/Phase 3 Study TKT024. All patients enrolling into this study received weekly active treatment with idursulfase. the primary dosing regimen